-
公开(公告)号：CA2762612A1
公开(公告)日：2010-12-16
申请号：CA2762612
申请日：2010-06-07
Applicant: SINGULEX INC
Inventor： GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD , HELD DOUGLAS , LE SARA
Abstract: Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnl, BNP) and vascular inflammation (IL-6, TNFa, IL- 17a) biomarkers provided a sensitivity of 94% for association with CHF.
-
公开(公告)号：AU2010259022B2
公开(公告)日：2016-05-12
申请号：AU2010259022
申请日：2010-06-07
Applicant: SINGULEX INC
Inventor： GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD , HELD DOUGLAS , LE SARA
Abstract: Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnl, BNP) and vascular inflammation (IL-6, TNFα, IL- 17a) biomarkers provided a sensitivity of 94% for association with CHF.
-
公开(公告)号：WO2009126380A8
公开(公告)日：2010-11-04
申请号：PCT/US2009036086
申请日：2009-03-04
Applicant: SINGULEX INC , GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD A , HELD DOUGLAS , AGEE SARA
Inventor： GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD A , HELD DOUGLAS , AGEE SARA
IPC: G01N33/53
CPC classification number: G01N33/577 , A61B5/00 , A61B5/0402 , A61B5/412 , A61B5/415 , A61B5/418 , A61B5/7264 , A61B5/7275 , G01N21/6428 , G01N33/582 , G01N33/6863 , G01N33/6869 , G01N33/6872 , G01N33/6887 , G01N33/6896 , G01N33/74 , G01N33/92 , G01N2333/4712 , G01N2333/475 , Y02A90/26 , Y10T436/143333
Abstract: The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnl) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg/ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker.
Abstract translation: 本发明公开了使用分子的高灵敏度检测来检测和监测受试者的状况的方法。 本发明提供了一种用于检测或监测受试者中的病症的方法，包括检测来自受试者的第一样品中的第一标志物并检测第二标志物，其中第一标记物包含生物标志物，例如心肌肌钙蛋白I（cTn1） 或血管内皮生长因子（VEGF），并且其中第一标记物的检测限小于约10pg / ml。 第二标记可以是生物标志物，生理学标记，分子标记或遗传标记。
-
公开(公告)号：AU2010259022A1
公开(公告)日：2011-12-01
申请号：AU2010259022
申请日：2010-06-07
Applicant: SINGULEX INC
Inventor： GOIX PHILIPPE J , ROBERT PUSKAS , JOHN TODD , RICHARD LIVINGSTON , DOUGLAS HELD , SARA LE
Abstract: Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnl, BNP) and vascular inflammation (IL-6, TNFα, IL- 17a) biomarkers provided a sensitivity of 94% for association with CHF.
-
公开(公告)号：CA2716522A1
公开(公告)日：2009-10-15
申请号：CA2716522
申请日：2009-03-04
Applicant: SINGULEX INC
Inventor： GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD A , HELD DOUGLAS , AGEE SARA
Abstract: The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnl) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg/ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker.
-
Patent Agency Ranking
公开(公告)号：AU2009234106A1
公开(公告)日：2009-10-15
申请号：AU2009234106
申请日：2009-03-04
Applicant: SINGULEX INC
Inventor： GOIX PHILIPPE J , HELD DOUGLAS , PUSKAS ROBERT , TODD JOHN , AGEE SARA , LIVINGSTON RICHARD A
Abstract: The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnI) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg/ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker.
-
公开(公告)号：GB2458025A
公开(公告)日：2009-09-09
申请号：GB0903848
申请日：2009-03-05
Applicant: SINGULEX INC
Inventor： GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD A , HELD DOUGLAS , AGEE SARA
Abstract: A method for detecting and monitoring a condition in a subject using a single molecule detector is disclosed comprising detecting a first marker in a first sample from the subject, wherein the first marker comprises a biomarker such as Cardiac Troponin-I (cTnI), and wherein the limit of detection of the first marker is less than 20 pg/ml, and further comprising the detection of a second marker as a further indication of the condition to be detected. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker. Also claimed are similar methods involving the detection of Vascular Endothelial Growth Factor (VEGF), pro B-type Natriuretic Peptide (proBNP), TREM-1, Interleukin 1 Alpha (IL-1 a ), IL- 1 b , IL-4, IL-6, IL-8, IL-10, Interferon gamma (IFN- q ), Tumour Necrosis Factor alpha (TNF- a ), Glucagon-like peptide-1 (GLP-1), Leukotriene E4 (LTE4), Transforming Growth Factor Beta (TGF- b ), Akt1, A b -40, A b -42, and Fas ligand (FasL). The markers may be detected using fluorescent labels.
-
公开(公告)号：WO2009126380A3
公开(公告)日：2009-12-03
申请号：PCT/US2009036086
申请日：2009-03-04
Applicant: SINGULEX INC , GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD A , HELD DOUGLAS , AGEE SARA
Inventor： GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD A , HELD DOUGLAS , AGEE SARA
IPC: G01N33/53
CPC classification number: G01N33/577 , A61B5/00 , A61B5/0402 , A61B5/412 , A61B5/415 , A61B5/418 , A61B5/7264 , A61B5/7275 , G01N21/6428 , G01N33/582 , G01N33/6863 , G01N33/6869 , G01N33/6872 , G01N33/6887 , G01N33/6896 , G01N33/74 , G01N33/92 , G01N2333/4712 , G01N2333/475 , Y02A90/26 , Y10T436/143333
Abstract: The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnl) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg/ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker.
Abstract translation: 本发明公开了使用分子的高灵敏度检测来检测和监测受试者状况的方法。 本发明提供了用于检测或监测受试者状况的方法，包括检测来自受试者的第一样品中的第一标志物和检测第二标志物，其中第一标志物包含生物标志物，例如心脏肌钙蛋白-I（cTnI） 或血管内皮生长因子（VEGF），并且其中第一标记的检测极限小于约10pg / ml。 第二个标记可以是生物标记，生理标记，分子标记或遗传标记。
-
公开(公告)号：EP2263085A4
公开(公告)日：2011-07-06
申请号：EP09731410
申请日：2009-03-04
Applicant: SINGULEX INC
Inventor： GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD A , HELD DOUGLAS , LE SARA
IPC: G01N33/53
CPC classification number: G01N33/577 , A61B5/00 , A61B5/0402 , A61B5/412 , A61B5/415 , A61B5/418 , A61B5/7264 , A61B5/7275 , G01N21/6428 , G01N33/582 , G01N33/6863 , G01N33/6869 , G01N33/6872 , G01N33/6887 , G01N33/6896 , G01N33/74 , G01N33/92 , G01N2333/4712 , G01N2333/475 , Y02A90/26 , Y10T436/143333
Abstract: The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnI) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg/ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker.
-
公开(公告)号：EP2440936A4
公开(公告)日：2013-03-13
申请号：EP10786631
申请日：2010-06-07
Applicant: SINGULEX INC
Inventor： GOIX PHILIPPE J , PUSKAS ROBERT , TODD JOHN , LIVINGSTON RICHARD , HELD DOUGLAS , LE SARA
CPC classification number: G01N33/6869 , G01N33/6893 , G01N2333/32 , G01N2333/47 , G01N2333/4712 , G01N2333/525 , G01N2333/54 , G01N2333/5412 , G01N2333/58 , G01N2800/32 , G01N2800/325 , G01N2800/60
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.032 seconds)
